Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Cash from Investing Activities: 2012-2024

Historic Cash from Investing Activities for Theravance Biopharma (TBPH) over the last 13 years, with Dec 2024 value amounting to $12.3 million.

  • Theravance Biopharma's Cash from Investing Activities fell 476.16% to -$100.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$90.2 million, marking a year-over-year decrease of 2110.98%. This contributed to the annual value of $12.3 million for FY2024, which is 137.57% up from last year.
  • As of FY2024, Theravance Biopharma's Cash from Investing Activities stood at $12.3 million, which was up 137.57% from -$32.7 million recorded in FY2023.
  • Over the past 5 years, Theravance Biopharma's Cash from Investing Activities peaked at $1.2 billion during FY2022, and registered a low of -$32.7 million during FY2023.
  • Over the past 3 years, Theravance Biopharma's median Cash from Investing Activities value was $12.3 million (recorded in 2024), while the average stood at $377.9 million.
  • In the last 5 years, Theravance Biopharma's Cash from Investing Activities surged by 1,061.22% in 2021 and then crashed by 102.83% in 2023.
  • Theravance Biopharma's Cash from Investing Activities (Yearly) stood at $10.7 million in 2020, then surged by 1,061.22% to $124.5 million in 2021, then soared by 826.96% to $1.2 billion in 2022, then plummeted by 102.83% to -$32.7 million in 2023, then spiked by 137.57% to $12.3 million in 2024.